Milnacipran: Beyond a Role of Antidepressant
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Marks, David M. | - |
dc.contributor.author | Shah, Manan | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Ham, Byung-Joo | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.date.available | 2020-11-03T07:47:15Z | - |
dc.date.issued | 2009-11 | - |
dc.identifier.issn | 0362-5664 | - |
dc.identifier.issn | 1537-162X | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15695 | - |
dc.description.abstract | Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. The half-life of milnacipran is approximately 8 hours. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating minimal propensity for drug-drug interactions. The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms. The current paper reviews researches conducted to date that is relevant to the efficacy, tolerability, and mechanism of action of milnacipran in the treatment of depression, fibromyalgia, and other psychiatric syndromes. Future directions of research are also identified. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | Milnacipran: Beyond a Role of Antidepressant | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/WNF.0b013e3181ac155b | - |
dc.identifier.scopusid | 2-s2.0-73349096343 | - |
dc.identifier.wosid | 000272362900014 | - |
dc.identifier.bibliographicCitation | CLINICAL NEUROPHARMACOLOGY, v.32, no.6, pp 355 - 363 | - |
dc.citation.title | CLINICAL NEUROPHARMACOLOGY | - |
dc.citation.volume | 32 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 355 | - |
dc.citation.endPage | 363 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | NORADRENALINE REUPTAKE INHIBITOR | - |
dc.subject.keywordPlus | MAJOR DEPRESSIVE DISORDER | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PANIC DISORDER | - |
dc.subject.keywordPlus | PSYCHIATRIC-DISORDERS | - |
dc.subject.keywordPlus | POSTSTROKE DEPRESSION | - |
dc.subject.keywordPlus | HEALTHY-VOLUNTEERS | - |
dc.subject.keywordPlus | NEUROPATHIC PAIN | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordAuthor | milnacipran | - |
dc.subject.keywordAuthor | antidepressant | - |
dc.subject.keywordAuthor | fibromyalgia | - |
dc.subject.keywordAuthor | pain | - |
dc.subject.keywordAuthor | fatigue | - |
dc.subject.keywordAuthor | anxiety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.